Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
about
Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complexCofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.Inflammatory concepts of obesity.Engineering Factor Viii for Hemophilia Gene Therapy.Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management.Blood Clotting Factor VIII: From Evolution to Therapy.Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.New products for the treatment of haemophilia.Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation.Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutationsLow levels of protein Z are associated with HELLP syndrome and its severity.Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.An Insight into the Sialomes of Bloodsucking Heteroptera
P2860
Q27659000-EBA1F1B7-E9E3-46A6-AEE5-1AA5C7C86470Q30360900-510EA9AE-D3E7-4985-88D0-2D585312EAAAQ34099771-F3D131F2-467E-4484-93F1-24198CB28515Q35151595-7DA0878C-29C1-4B10-959D-01BF048406B6Q36737263-7A6DB776-2828-4390-A232-410EFA81B3BEQ36801646-450DDBC9-583B-4B26-A553-2753C6D313E4Q36863328-8E29EAEA-7F76-43FF-90C2-B5670D0E4B34Q36915872-6A2BC2B9-EEBC-4F76-92C2-9643E64F5D72Q38044505-E3022EA7-8A85-4C09-8CFB-76F0A88BEB9DQ38118763-C3ABEC5D-605B-41CD-B587-A7EDDA8ED160Q38175362-2E2810EE-B6AC-499F-829E-D92F3E67DBE5Q38604626-C87812A3-3350-45C5-BB99-E8F42BC65143Q41786857-C756E8CB-EE46-4B8B-B37E-04EF05EF491DQ42038531-244B0010-35A4-4B8B-9CC7-0B8F56022B9EQ46729216-E6B8562B-8AC8-470D-83EE-00E588D646E0Q55013009-D8F1CCCC-CA65-4646-83FD-1248001485A7Q57164183-F740FD82-18E8-4016-99DB-AB7FBC98F707
P2860
Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Disulfide bond-stabilized fact ...... n whole blood clotting assays.
@en
type
label
Disulfide bond-stabilized fact ...... n whole blood clotting assays.
@en
prefLabel
Disulfide bond-stabilized fact ...... n whole blood clotting assays.
@en
P2093
P2860
P1476
Disulfide bond-stabilized fact ...... n whole blood clotting assays.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2006.02283.X
P577
2006-10-24T00:00:00Z